Oramed gets roughed up

|About: Oramed Pharmaceuticals... (ORMP)|By:, SA News Editor

Shares of Oramed Pharmaceuticals (ORMP) are down 13% on average volume today as the sell-off continues from its recent parabolic up move that began on December 20.

Prices rocketed 360% on investors' brief enthusiasm over its insulin pill only to quickly retreat after various observers began scrutinizing the situation.

Oramed's market cap is $121M.

Six mutual funds have positions, up from two a year earlier.